Allogene Therapeutics, Inc. (ALLO)

$2.3

-0.05

(-2.13%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Allogene Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 21.0K → 22.0K (in $), with an average increase of 4.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -85.77M → -65.0M (in $), with an average increase of 32.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.1% return, outperforming this stock by 126.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 331.8%

Performance

  • $2.24
    $2.39
    $2.30
    downward going graph

    2.61%

    Downside

    Day's Volatility :6.28%

    Upside

    3.77%

    downward going graph
  • $2.23
    $6.05
    $2.30
    downward going graph

    3.04%

    Downside

    52 Weeks Volatility :63.14%

    Upside

    61.98%

    downward going graph

Returns

PeriodAllogene Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-45.17%
0.6%
0.0%
6 Months
-20.96%
8.9%
0.0%
1 Year
-52.18%
10.2%
0.0%
3 Years
-90.6%
17.8%
-20.9%

Highlights

Market Capitalization
490.6M
Book Value
$2.71
Earnings Per Share (EPS)
-1.78
Wall Street Target Price
11.51
Profit Margin
0.0%
Operating Margin TTM
-315927.27%
Return On Assets TTM
-26.71%
Return On Equity TTM
-55.48%
Revenue TTM
87.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-26.700000000000003%
Gross Profit TTM
243.0K
EBITDA
-270.7M
Diluted Eps TTM
-1.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.49
EPS Estimate Next Year
-1.55
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    73%Buy
    26%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Allogene Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
17
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 400.43%

Current $2.30
Target $11.51

Technicals Summary

Sell

Neutral

Buy

Allogene Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
-11.2%
-20.96%
-52.18%
-90.6%
-91.84%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
NA
NA
NA
-1.49
-0.55
-0.27
NA
2.71
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
Buy
$490.6M
-91.84%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Institutional Holdings

  • FMR Inc

    12.15%
  • TPG GP A, LLC

    8.96%
  • BlackRock Inc

    4.62%
  • State Street Corporation

    4.40%
  • Vanguard Group Inc

    3.93%
  • PRIMECAP Management Company

    2.61%

Company Information

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le

Organization
Allogene Therapeutics, Inc.
Employees
232
CEO
Dr. Arie S. Belldegrun F.A.C.S., M.D.
Industry
Health Technology

FAQs